# OnCo record paper-nct05724563-nat-commun-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-nct05724563-nat-commun-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-nct05724563-nat-commun-2025" ;
  schema:name "Dual TIGIT and PD-1 blockade with domvanalimab plus zimberelimab in hepatocellular carcinoma refractory to anti-PD-1 therapies: the phase 2 LIVERTI trial"@en ;
  schema:description "Published report from the trial registered as NCT05724563, in Nature Communications (2025), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-nct05724563-nat-commun-2025/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://doi.org/10.1038/s41467-025-60757-7>, <https://pubmed.ncbi.nlm.nih.gov/40592848/>, <https://europepmc.org/article/MED/40592848>, <https://clinicaltrials.gov/study/NCT05724563> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1038/s41467-025-60757-7> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Hsiehchen D, Kainthla R, Kline H, et al." ;
  onco:trials <https://onco.cc/trials/nct05724563/> ;
  onco:journals <https://onco.cc/journals/nature-communications/> .